INVO Bioscience, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 1.58 million compared to USD 0.348025 million a year ago. Net loss was USD 1.6 million compared to USD 2.55 million a year ago.

Basic loss per share from continuing operations was USD 0.42 compared to USD 4.1 a year ago. Diluted loss per share from continuing operations was USD 0.42 compared to USD 4.1 a year ago.